Top 10 Companies in the Southeast Asia Atypical Antipsychotic Drugs Market (2026): Market Leaders Driving Global Mental Health Care

MARKET INSIGHTS

The Southeast Asia Atypical Antipsychotic Drugs market size was valued at USD 678 million in 2024. The market is projected to grow from USD 717 million in 2025 to USD 1,058 million by 2032, exhibiting a CAGR of 5.7% during the forecast period.

Atypical antipsychotics are second‑generation antipsychotic medications used to treat various psychiatric disorders. These drugs primarily target conditions such as schizophrenia, bipolar I disorder, schizoaffective disorder, and major depressive disorder by balancing neurotransmitters such as dopamine and serotonin in the brain. Unlike first‑generation antipsychotics, they generally offer a lower risk of extrapyramidal side effects, making them a preferred choice in modern psychiatric care. Key products include risperidone, olanzapine, quetiapine, ziprasidone, and others.

The market is experiencing steady growth due to rising awareness and improved diagnosis of mental health issues across the region. Expanding healthcare infrastructure and better insurance coverage in nations like Thailand and Indonesia are enhancing accessibility. However, challenges such as patent expirations and intensifying generic competition could impact pricing. Opportunities lie in developing formulations with fewer side effects and higher efficacy. Major players including Johnson & Johnson, Pfizer Inc., Eli Lilly and Company, AstraZeneca, and Bristol‑Myers Squibb are driving innovation through research and strategic partnerships to meet evolving demands.

Southeast Asia Atypical Antipsychotic Drugs Market – View in Detailed Research Report

1. Johnson & Johnson (USA)

   Headquarters: New Brunswick, New Jersey, USA
   Key Offering: Risperidone, Olanzapine, and a portfolio of second‑generation antipsychotics

   Johnson & Johnson has leveraged its extensive R&D capabilities and global distribution network to maintain a dominant presence in the Southeast Asian market. The company focuses on delivering high‑quality, clinically validated therapies that address the region’s growing psychiatric burden.

   Sustainability & Growth Initiatives:

   • Investing in digital health platforms to improve patient adherence
   • Expanding local manufacturing to reduce supply chain costs
   • Collaborating with regional health ministries to support mental health policy development

2. Pfizer Inc. (USA)

   Headquarters: New York, New York, USA
   Key Offering: Risperidone, Quetiapine, and innovative formulations

   Pfizer’s strategic partnerships and robust pipeline of next‑generation antipsychotics position it as a key innovator in the Southeast Asian market.

   Sustainability & Growth Initiatives:

   • Developing long‑acting injectable formulations to improve adherence
   • Implementing cost‑effective generic strategies post‑patent expiration
   • Supporting telepsychiatry initiatives to increase reach in underserved areas

3. Eli Lilly and Company (USA)

   Headquarters: Indianapolis, Indiana, USA
   Key Offering: Risperidone, Olanzapine, and specialty formulations

   Eli Lilly focuses on high‑impact therapeutic areas and partners with local distributors to enhance market penetration.

   Sustainability & Growth Initiatives:

   • Investing in digital therapeutics for integrated care
   • Expanding research collaborations with regional universities
   • Promoting patient education programs to reduce discontinuation rates

4. AstraZeneca (UK/Sweden)

   Headquarters: Cambridge, UK
   Key Offering: Risperidone, Quetiapine, and novel antipsychotics

   AstraZeneca’s portfolio emphasizes efficacy and safety, backed by extensive clinical evidence.

   Sustainability & Growth Initiatives:

   • Launching long‑acting injectable options in key markets
   • Adopting green manufacturing practices to reduce carbon footprint
   • Supporting community mental health programs through CSR initiatives

5. Bristol‑Myers Squibb (USA)

   Headquarters: New York, New York, USA
   Key Offering: Risperidone and specialty formulations

   Bristol‑Myers Squibb prioritizes innovation in psychiatric therapeutics and collaborates with local health systems.

   Sustainability & Growth Initiatives:

   • Developing precision medicine approaches for schizophrenia
   • Implementing patient support programs to improve adherence
   • Partnering with NGOs to enhance mental health awareness

6. Otsuka Pharmaceutical Co., Ltd. (Japan)

   Headquarters: Tokyo, Japan
   Key Offering: Risperidone and other atypical antipsychotics

   Otsuka leverages its strong presence in the Asia‑Pacific region to deliver affordable, high‑quality therapies.

   Sustainability & Growth Initiatives:

   • Expanding local production facilities to meet regional demand
   • Investing in research on metabolic side‑effect mitigation
   • Supporting community outreach programs for mental health education

7. Novartis AG (Switzerland)

   Headquarters: Basel, Switzerland
   Key Offering: Risperidone, Quetiapine, and specialty formulations

   Novartis focuses on high‑quality generics and innovative delivery systems.

   Sustainability & Growth Initiatives:

   • Developing long‑acting injectable antipsychotics
   • Implementing cost‑effective manufacturing to support price competitiveness
   • Engaging in public‑private partnerships to improve access

8. GlaxoSmithKline plc (UK)

   Headquarters: Brentford, United Kingdom
   Key Offering: Risperidone, Olanzapine, and other atypical antipsychotics

   GSK emphasizes patient‑centric care and supports mental health initiatives across Southeast Asia.

   Sustainability & Growth Initiatives:

   • Expanding digital health solutions for remote monitoring
   • Adopting sustainable sourcing practices for raw materials
   • Collaborating with local NGOs to reduce stigma

9. Teva Pharmaceutical Industries Ltd. (Israel)

   Headquarters: Jerusalem, Israel
   Key Offering: Generic risperidone, olanzapine, and other second‑generation antipsychotics

   Teva’s extensive generic portfolio addresses price sensitivity in emerging markets.

   Sustainability & Growth Initiatives:

   • Scaling up local manufacturing to reduce import costs
   • Investing in research on metabolic side‑effect reduction
   • Providing patient support programs to improve adherence

10. Allergan plc (Ireland)

    Headquarters: Dublin, Ireland
    Key Offering: Specialty antipsychotics and formulation innovations

    Allergan focuses on niche therapeutic areas and advanced delivery technologies.

    Sustainability & Growth Initiatives:

    • Developing long‑acting injectable formulations
    • Implementing green manufacturing processes
    • Partnering with local health authorities for mental health outreach

Download FREE Sample Report: Southeast Asia Atypical Antipsychotic Drugs Market – View in Detailed Research Report

Get Full Report: Southeast Asia Atypical Antipsychotic Drugs Market – View in Detailed Research Report

OUTLOOK

The Southeast Asia Atypical Antipsychotic Drugs market is projected to expand steadily, with a forecasted CAGR of 5.7% from 2025 through 2034. Key growth drivers include increasing mental health awareness, expanding healthcare infrastructure, and improved insurance coverage in countries such as Thailand, Indonesia, and Vietnam. The market will also benefit from ongoing innovation in long‑acting injectable formulations and digital health integration, which are expected to enhance patient adherence and broaden access.

Future Trends

Emerging trends in the market encompass the development of novel drug delivery systems, including long‑acting injectables that reduce metabolic side effects and improve therapeutic outcomes. Digital health platforms and telepsychiatry are gaining traction, offering new avenues for diagnosis, prescription, and patient monitoring. Strategic partnerships between multinational corporations and local manufacturers will drive technology transfer and cost‑effective production, while the growing medical tourism sector in Malaysia and Thailand presents opportunities for specialized mental health treatments.